The J. David Gladstone Institutes, Taube Philanthropies, and the Koret Foundation joined forces to initiate a research program aimed at preventing, treating, or curing Huntington's disease (HD) by 2020.
The new Taube-Koret Center for Huntington's Disease Research has been established at the Gladstone Center for Translational Research at Mission Bay, CA, with $3.6 million in funding from the two organizations. The program is called HD Cure 2020.
The center will build on research from investigators Steven Finkbeiner, M.D., Ph.D., and Paul Muchowski, Ph.D., of the Gladstone Institute of Neurological Disease (GIND) related to assay development and molecular targets that may modulate HD progression.
Dr. Finkbeiner’s technologies reportedly aid in the understanding of HD etiology and pathology. Dr. Muchowski’s studies have identified intracellular pathways that modify progression of the disease. Together they have also developed methods to find and screen small molecules that may work to modulate the disease.
“While so much is known about Huntington's disease, it remains an unsolved mystery,” notes Dr. Finkbeiner. “Over the last few years, we have been able to find new points of entry into how the disease progresses and where we might possibly intervene.”